Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stock Holdings Increased by Wells Fargo & Company MN

Wells Fargo & Company MN boosted its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 43.7% in the fourth quarter, HoldingsChannel reports. The firm owned 103,384 shares of the company’s stock after purchasing an additional 31,457 shares during the quarter. Wells Fargo & Company MN’s holdings in Taysha Gene Therapies were worth $179,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Cibc World Markets Corp acquired a new position in Taysha Gene Therapies during the 4th quarter valued at about $28,000. E Fund Management Co. Ltd. bought a new position in Taysha Gene Therapies in the 4th quarter worth approximately $31,000. AXQ Capital LP acquired a new stake in Taysha Gene Therapies in the 4th quarter valued at approximately $39,000. Commonwealth Equity Services LLC raised its stake in Taysha Gene Therapies by 110.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 59,069 shares of the company’s stock valued at $102,000 after acquiring an additional 31,000 shares in the last quarter. Finally, LPL Financial LLC acquired a new position in Taysha Gene Therapies during the 4th quarter worth $104,000. 77.70% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, April 10th. Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Monday, April 28th. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $6.63.

Taysha Gene Therapies Trading Up 1.4 %

NASDAQ TSHA opened at $2.13 on Friday. Taysha Gene Therapies, Inc. has a 12 month low of $1.05 and a 12 month high of $4.32. The company has a market cap of $436.77 million, a PE ratio of 3.38 and a beta of 0.90. The stock has a 50 day moving average of $1.65 and a 200-day moving average of $1.81. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. The business had revenue of $2.02 million during the quarter, compared to analysts’ expectations of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. On average, equities research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.